Despite the marked advances in drug therapy, some patients do not respond favorably or
suffer severe adverse drug effects. Pharmacogenetic studies have shown that …

The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate
glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination …

Despite initial enthusiasm, 1, 2, 3 the use of pharmacogenetics has remained limited to
investigation in only a few clinical fields such as oncology and psychiatry. 4, 5, 6, 7, 8 The …

Warfarin anticoagulation effect is characterized by marked variability, some of which has
been attributed to CYP2C9 polymorphisms. This study prospectively examines whether a …

Objectives SN-38, an active metabolite of irinotecan, is detoxified by glucuronidation with
UGT1A isoforms, 1A1, 1A7, 1A9, and 1A10. The pharmacogenetic information on UGT1A …

Purpose To determine whether uridine diphosphate-glucuronosyltransferase 1A1, UGT1A7,
and UGT1A9 polymorphisms affect the pharmacokinetics (PK) of irinotecan and treatment …

The current 'fixed-dosage strategy'approach to medicine, means there is much inter-
individual variation in drug response. Pharmacogenetics is the study of how inter-individual …

Featuring more than 4100 references, Drug-Induced Liver Disease is an invaluable
reference for gastroenterologists, hepatologists, family physicians, internists, pathologists …

The anticancer agent irinotecan (CPT-11) is converted to SN-38, which is approximately 100
to 1000-fold more cytotoxic than the parent drug. The pharmacokinetics of irinotecan are …

Background Unconjugated hyperbilirubinemia results from Gilbert syndrome and from
antiretroviral therapy (ART) containing protease inhibitors. An understanding of the …